-
Mashup Score: 23Immunogenetic Diversity and Cancer Immunotherapy Disparities - 13 day(s) ago
Summary:. The success of checkpoint blockade cancer immunotherapies has unequivocally confirmed the critical role of T cells in cancer immunity and boosted the development of immunotherapeutic strategies targeting specific antigens on cancer cells. The vast immunogenetic diversity of human leukocyte antigen (HLA) class I alleles across populations is a key factor influencing the advancement of HLA class I–restricted therapies and related research and diagnostic tools.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41Cancer Immunotherapy: From bench to bedside and back - 3 month(s) ago
Join me at this event!
Source: conferences.nature.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 0The Cancer Moonshot Immuno-Oncology Translational Network (IOTN) at age 5: Accelerating Cancer Immunotherapies - 7 month(s) ago
Abstract. The Immuno-Oncology Translational Network (IOTN) was established in 2018 as part of the Cancer MoonshotSM, and in 2022 President Biden set new goals t
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0The Cancer Moonshot Immuno-Oncology Translational Network (IOTN) at age 5: Accelerating Cancer Immunotherapies - 7 month(s) ago
Abstract. The Immuno-Oncology Translational Network (IOTN) was established in 2018 as part of the Cancer MoonshotSM, and in 2022 President Biden set new goals t
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Abstract. The ability of T-cell receptors (TCR) to recognize tumor-associated antigens (TAA) is a key driver of adoptive transfer of tumor-infiltrating lymphocyte (TIL) T cells, which can be a highly effective cancer immunotherapy. While it is common knowledge that TCRs are cross-reactive and can bind multiple different peptide antigens, this is typically considered an unattractive feature and limitation for TCR-based therapies. In a recent publication in Cell, Dolton and colleagues discover that certain TCRs, isolated from TILs used for successful treatment of melanoma, possess beneficial cross-reactivity by recognizing multiple TAA. Moreover, they elucidate the cumulative value of TCR cross-reactivity on cancer cell eradication and its prospective advantages for targeted cancer immunotherapies.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Uncovering the Role of CD4+ CAR T Cells in Cancer Immunotherapy - 9 month(s) ago
Abstract. Chimeric antigen receptor (CAR) T cell therapy has transformed clinical care against blood malignancies and is seeing encouraging progress against solid tumors. While scientific advancement has been rapid, our mechanistic understanding of intrinsic features of CAR-engineered T cells is still evolving. CAR products typically consist of CD4+ and CD8+ T cell subsets at variable ratios, yet a clear understanding of how each subset contributes together and independently to therapeutic response is lacking. CD8+ CAR T cells are well-characterized for their perforin-dependent killing effects; however, the role of CD4+ CAR T cells as ‘helpers’ versus ‘killers’ has been variable across models and warrants more in-depth investigation. A recent study by Boulch and colleagues published in Nature Cancer demonstrates that CD4+ CAR T cells, alone, can exert potent antitumor activity through a mechanism involving IFNγ. CD4+ CAR T cell production of IFNγ creates a cytokine field that can act a
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Uncovering the Role of CD4+ CAR T Cells in Cancer Immunotherapy - 10 month(s) ago
Abstract. Chimeric antigen receptor (CAR) T cell therapy has transformed clinical care against blood malignancies and is seeing encouraging progress against solid tumors. While scientific advancement has been rapid, our mechanistic understanding of intrinsic features of CAR-engineered T cells is still evolving. CAR products typically consist of CD4+ and CD8+ T cell subsets at variable ratios, yet…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Study hints at how cancer immunotherapy can be safer - 11 month(s) ago
Cancer immunotherapy has revolutionized treatment of many forms of cancer by unleashing the immune system response against tumors. Immunotherapies that block checkpoint receptors like PD-1, proteins that limit the capacity of T cells to attack tumors, have become the choice for the treatment of numerous types of solid cancer.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 13
Cancer immunotherapy has transformed the treatment of many types of cancer. Yet, for reasons that remain poorly understood, not all patients get the same benefit from these powerful therapies.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents. Here, we demonstrate in mouse models that neutrophils can be …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
Read a Special Commentary from the April issue— Immunogenetic Diversity and #CancerImmunotherapy Disparities, by @NFdeMiranda and @LabScheeren. https://t.co/kXmDEymvP7 @LUMC_Leiden https://t.co/gGKIUAzvPZ